Paroxetine: current status in psychiatry

References

• Bang LM, Keating GM. Paroxetine controlled release. CNS Drugs18(6), 355–364; discussion 365–356 (2004).
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Valuck R, Saseen J, MacFall HM. A comparison of the direct costs and cost–effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs18(13), 911–932 (2004).
   PubMed Web of Science ®Google Scholar
• Anderson IM. SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress. Anxiety7(Suppl. 1), 11–17 (1998).
   PubMedGoogle Scholar
• Carrasco JL, Sandner C. Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview. Int. J. Clin. Pract.59(12), 1428–1434 (2005).
   PubMed Web of Science ®Google Scholar
• Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs57(4), 507–533 (1999).
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry163(1), 28–40 (2006).
   PubMed Web of Science ®Google Scholar
• Heydorn WE. Paroxetine: a review of its pharmacology, pharmacokinetics and utility in the treatment of a variety of psychiatric disorders. Expert Opin. Investig. Drugs8(4), 417–441 (1999).
   PubMedGoogle Scholar
• Greb WH, Brett MA, Buscher G et al. Absorption of paroxetine under various dietary conditions and following antacid intake. Acta Psychiatr. Scand.350, 99–101 (1989).
   Google Scholar
• Wagstaff AJ, Cheer SM, Matheson AJ, Ormrod D, Goa KL. Paroxetine: an update of its use in psychiatric disorders in adults. Drugs62(4), 655–703 (2002).
   PubMed Web of Science ®Google Scholar
• Kaye CM, Haddock RE, Langley PF et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr. Scand.350(Suppl.), 60–75 (1989).
   Google Scholar
• Gunasekara NS, Noble S, Benfield P. Paroxetine. An update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs55(1), 85–120 (1998).
   PubMed Web of Science ®Google Scholar
• Dalhoff K, Almdal TP, Bjerrum K et al. Pharmacokinetics of paroxetine in patients with cirrhosis. Eur. J. Clin. Pharmacol.41(4), 351–354 (1991).
   PubMed Web of Science ®Google Scholar
• Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin. Pharmacokinet.32(Suppl. 1), 1–21 (1997).
   PubMed Web of Science ®Google Scholar
• Pollock BG, Mulsant BH, Nebes R et al. Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline. Am. J. Psychiatry155(8), 1110–1112 (1998).
   PubMed Web of Science ®Google Scholar
• Gilmor ML, Owens MJ, Nemeroff CB. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am. J. Psychiatry159(10), 1702–1710 (2002).
   PubMed Web of Science ®Google Scholar
• Nemeroff CB, Owens MJ. Neuropharmacology of paroxetine. Psychopharmacol. Bull.37(Suppl. 1), 8–18 (2003).
   PubMedGoogle Scholar
• Le Poul E, Laaris N, Doucet E et al. Early desensitization of somato-dendritic 5-HT1A autoreceptors in rats treated with fluoxetine or paroxetine. Naunyn Schmiedebergs Arch. Pharmacol.352(2), 141–148 (1995).
   PubMed Web of Science ®Google Scholar
• Chaput Y, de Montigny C, Blier P. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat. Neuropsychopharmacology5(4), 219–229 (1991).
   PubMed Web of Science ®Google Scholar
• Wilson SJ, Bailey JE, Rich AS et al. Using sleep to evaluate comparative serotonergic effects of paroxetine and citalopram. Eur. Neuropsychopharmacol.14(5), 367–372 (2004).
   PubMedGoogle Scholar
• Bell C, Wilson S, Rich A, Bailey J, Nutt D. Effects on sleep architecture of pindolol, paroxetine and their combination in healthy volunteers. Psychopharmacology (Berl.)166(2), 102–110 (2003).
   PubMed Web of Science ®Google Scholar
• Paxil® package insert. GlaxoSmithKline, PA, USA (2006).
   Google Scholar
• Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int. Clin. Psychopharmacol.8(3), 189–195 (1993).
   PubMed Web of Science ®Google Scholar
• Ballenger JC. Remission rates in patients with anxiety disorders treated with paroxetine. J. Clin. Psychiatry65(12), 1696–1707 (2004).
   PubMed Web of Science ®Google Scholar
• Reynolds CF 3rd, Dew MA, Pollock BG et al. Maintenance treatment of major depression in old age. N. Engl. J. Med.354(11), 1130–1138 (2006).
   PubMed Web of Science ®Google Scholar
• Reynolds CF 3rd. Paroxetine treatment of depression in late life. Psychopharmacol. Bull.37(Suppl. 1), 123–134 (2003).
   PubMedGoogle Scholar
• Stocchi F, Nordera G, Jokinen RH et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J. Clin. Psychiatry64(3), 250–258 (2003).
   PubMed Web of Science ®Google Scholar
• Holroyd KA, Labus JS, O’Donnell FJ, Cordingley GE. Treating chronic tension-type headache not responding to amitriptyline hydrochloride with paroxetine hydrochloride: a pilot evaluation. Headache43(9), 999–1004 (2003).
   PubMedGoogle Scholar
• Verkes RJ, Van der Mast RC, Hengeveld MW et al. Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. Am. J. Psychiatry155(4), 543–547 (1998).
   PubMed Web of Science ®Google Scholar
• Ansari A. The efficacy of newer antidepressants in the treatment of chronic pain: a review of current literature. Harv. Rev. Psychiatry7(5), 257–277 (2000).
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Hansen RA, Carey TS et al. Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis. Int. Clin. Psychopharmacol.20(2), 59–69 (2005).
   PubMed Web of Science ®Google Scholar
• Schatzberg AF, Blier P, Delgado PL et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J. Clin. Psychiatry67(Suppl. 4), 27–30 (2006).
   PubMedGoogle Scholar
• Bogetto F, Bellino S, Revello RB, Patria L. Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation. CNS Drugs16(4), 273–283 (2002).
   PubMedGoogle Scholar
• Price JS, Waller PC, Wood SM, MacKay AV. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br. J. Clin. Pharmacol.42(6), 757–763 (1996).
   PubMed Web of Science ®Google Scholar
• Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. Br. J. Clin. Pharmacol.16(5), 356–362 (1996).
   Google Scholar
• Stahl MM, Lindquist M, Pettersson M et al. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur. J. Clin. Pharmacol.53(3–4), 163–169 (1997).
   PubMed Web of Science ®Google Scholar
• Sir A, D’Souza RF, Uguz S et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J. Clin. Psychiatry66(10), 1312–1320 (2005).
   PubMed Web of Science ®Google Scholar
• Blier P, Tremblay P. Physiologic mechanisms underlying the antidepressant discontinuation syndrome. J. Clin. Psychiatry67(Suppl. 4), 8–13 (2006).
   PubMed Web of Science ®Google Scholar
• Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J. Clin. Psychopharmacol.19(1), 67–85 (1999).
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Baldwin DS, Riley A. Antidepressant medications: a review of the evidence for drug-induced sexual dysfunction. J. Affect. Disord.69(1–3), 119–140 (2002).
   PubMed Web of Science ®Google Scholar
• Montejo-Gonzalez AL, Llorca G, Izquierdo JA et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J. Sex Marital Ther.23(3), 176–194 (1997).
   PubMed Web of Science ®Google Scholar
• Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders – III. Tolerability, safety and pharmacoeconomics. J. Psychopharmacol.12(3 Suppl. B), S55–S87 (1998).
   PubMed Web of Science ®Google Scholar
• Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann. Clin. Psychiatry17(2), 65–69 (2005).
   PubMedGoogle Scholar
• Ferguson JM. SSRI Antidepressant medications: adverse effects and tolerability. prim care companion J. Clin. Psychiatry3(1), 22–27 (2001).
   Google Scholar
• Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J. Clin. Psychiatry61(11), 863–867 (2000).
   PubMed Web of Science ®Google Scholar
• Bandelow B, Behnke K, Lenoir S et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. J. Clin. Psychiatry65(3), 405–413 (2004).
   PubMed Web of Science ®Google Scholar
• Kallen B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod. Toxicol.21(3), 221–222 (2006).
   PubMed Web of Science ®Google Scholar
• Kulin NA, Pastuszak A, Sage SR et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA279(8), 609–610 (1998).
   PubMed Web of Science ®Google Scholar
• Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur. J. Clin. Pharmacol.55(7), 503–508 (1999).
   PubMed Web of Science ®Google Scholar
• Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiol. Drug Saf.14(12), 823–827 (2005).
   PubMed Web of Science ®Google Scholar
• Sanz EJ, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet365(9458), 482–487 (2005).
   PubMed Web of Science ®Google Scholar
• Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch. Pediatr. Adolesc. Med.160(2), 173–176 (2006).
   PubMed Web of Science ®Google Scholar
• Chambers CD, Hernandez-Diaz S, Van Marter LJ et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N. Engl. J. Med. (354), 579–587 (2006).
   PubMedGoogle Scholar
• Cohen L, Nonacs R. Center for women’s mental health E-newsletter: reviewing the safety of SSRI’s in pregnancy.2, 1–9 (2006).
   Google Scholar
• Patkar AA , Bilal L, Masand PS. Pharmacotherapy of depression in pregnancy. Ann. Clin. Psychiatry16, 87–100 (2004).
   PubMedGoogle Scholar
• Newman TB. A black-box warning for antidepressants in children? N. Engl. J. Med.351(16), 1595–1598 (2004).
   PubMed Web of Science ®Google Scholar
• Healy D. Did regulators fail over selective serotonin reuptake inhibitors? Br. Med. J.333(7558), 92–95 (2006).
   PubMedGoogle Scholar
• Lenzer J. Company admits increase in suicidal behaviour in patients taking paroxetine. Br. Med. J.332, 1175 (2006).
   PubMedGoogle Scholar
• Glasser M, Amdur MJ, Backstrand J. The impact of psychotherapists and primary physicians on suicide and other violent deaths in a rural area. Can. J. Psychiatry.30(3), 195–202 (1985).
   PubMedGoogle Scholar
• Gibbons RD HK, Bhaumik DK, Mann JJ. The relationship between antidepressant medication use and rate of suicide. Arch. Gen. Psychiatry62, 165–172 (2005).
   PubMed Web of Science ®Google Scholar
• Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am. J. Psychiatry163(1), 41–47 (2006).
   PubMed Web of Science ®Google Scholar
• Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA292(3), 338–343 (2004).
   PubMed Web of Science ®Google Scholar
• Emslie GJ, Wagner KD, Kutcher S et al. Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J. Am. Acad. Child Adolesc. Psychiatry45(6), 709–719 (2006).
   PubMed Web of Science ®Google Scholar
• Keller MB, Ryan ND, Strober M et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J. Am. Acad. Child Adolesc. Psychiatry40(7), 762–772 (2001).
   PubMed Web of Science ®Google Scholar
• Geller DA, Wagner KD, Emslie G et al. Paroxetine treatment in children and adolescents with obsessive–compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J. Am. Acad. Child Adolesc. Psychiatry43(11), 1387–1396 (2004).
   PubMed Web of Science ®Google Scholar
• Wagner KD, Berard R, Stein MB et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch. Gen. Psychiatry61(11), 1153–1162 (2004).
   PubMed Web of Science ®Google Scholar
• Paxil CR®. GlaxoSmithKline, PA, USA (2006).
   Google Scholar
• Golden RN, Nemeroff CB, McSorley P, Pitts CD, Dube EM. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J. Clin. Psychiatry63(7), 577–584 (2002).
   PubMed Web of Science ®Google Scholar
• Golden RN. Efficacy and tolerability of controlled-release paroxetine. Psychopharmacol. Bull.37(Suppl. 1), 176–186 (2003).
   PubMedGoogle Scholar
• DeVane C, Carpenter D, Nucci G, Lipschitz A, Perera P. Immediate vs controlled release paroxetine: PK profiles at steady state and impact of CYP2D6 metabolizer status. Annual meeting of NCDEU (2004).
   Google Scholar
• DeVane CL. Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. J. Clin. Psychiatry64(Suppl. 18), 14–19 (2003).
   PubMedGoogle Scholar
• Dunner DL, Lipschitz A, Pitts CD, Davies JT. Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials. Clin. Ther.27(12), 1901–1911 (2005).
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Pigotti TA, Perera P et al. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. J. Clin. Psychiatry65(10), 1356–1364 (2004).
   PubMed Web of Science ®Google Scholar
• Rapaport MH, Schneider LS, Dunner DL, Davies JT, Pitts CD. Efficacy of controlled-release paroxetine in the treatment of late-life depression. J. Clin. Psychiatry64(9), 1065–1074 (2003).
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Burnham DB, Iyengar MK, Perera P. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J. Clin. Psychiatry66(1), 34–40 (2005).
   PubMed Web of Science ®Google Scholar
• Lepola U, Bergtholdt B, St Lambert J, Davy KL, Ruggiero L. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J. Clin. Psychiatry65(2), 222–229 (2004).
   PubMed Web of Science ®Google Scholar
• Steiner M, Hirschberg AL, Bergeron R et al. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Am. J. Obstet. Gynecol.193(2), 352–360 (2005).
   PubMed Web of Science ®Google Scholar
• Pearlstein TB, Bellew KM, Endicott J, Steiner M. Paroxetine controlled release for premenstrual dysphoric disorder: remission analysis following a randomized, double-blind, placebo-controlled trial. Prim. Care Companion J. Clin. Psychiatry7(2), 53–60 (2005).
   PubMedGoogle Scholar
• Cohen LS, Soares CN, Yonkers KA et al. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial. Psychosom. Med.66(5), 707–713 (2004).
   PubMed Web of Science ®Google Scholar
• Liebowitz MR. Social phobia. Mod Probl. Pharmacopsychiatry22, 141–173 (1987).
   PubMedGoogle Scholar
• GlaxosmithKline. A Randomized, Double-Blind, Placebo-Controlled, Flexible Dosage Trial to Evaluate the Efficacy and Tolerability of Paroxetine CR in Patients with Generalized Anxiety Disorder Study No.: 29060/791. (GAD) (2005).
   Google Scholar
• GlaxoSmithKline. A Double-blind, Placebo-controlled, Fixed-dosage Study Comparing the Efficacy and Tolerability of Paroxetine CR and Citalopram to Placebo in the Treatment of Major Depressive Disorder with anxiety Study No.: 29060/785. (2005).
   Google Scholar
• Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA289(21), 2827–2834 (2003).
   PubMed Web of Science ®Google Scholar
• Patkar A, Peindl K, Krulewicz S et al. History of depressive and anxiety disorders as predictors of response in fibromyalgia. Presented at: 158th Annual Meeting of the American Psychiatric Association. Atlanta, GA, USA (2005).
   Google Scholar
• Masand PS, Pae C, Krulewicz S et al. A double-blind, randomized, placebo-controlled, trial of Paroxetine controlled release in irritable bowel syndrome. Psychosomatics (2006) (In Press).
   Google Scholar
• Bull SA, Hunkeler EM, Lee JY et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann. Pharmacother.36(4), 578–584 (2002).
   PubMed Web of Science ®Google Scholar
• Golden R, Perera P, Holdsworth SEA. Tolerability of controlled and immediate release SSRIs in the treatment of major depression and anxiety disorders. Presented at: American Psychiatric Association (APA) Annual Meeting. San Francisco, CA, USA, 17–22 May 2003.
   Google Scholar
• Keene MS, Eaddy MT, Mauch RP et al. Differences in compliance patterns across the selective serotonin reuptake inhibitors (SSRIs). Curr. Med. Res. Opin.21(10), 1651–1658 (2005).
   PubMed Web of Science ®Google Scholar
• Keene MS, Eaddy MT, Nelson WW, Sarnes MW. Adherence to paroxetine CR compared with paroxetine IR in a medicare-eligible population with anxiety disorders. Am. J. Manag. Care11(Suppl. 12), S362–S369 (2005).
   Google Scholar
• Sheehan DV, Eaddy M, Sarnes M, Vishalpura T, Regan T. Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetine. J. Clin. Psychopharmacol.24(5), 544–548 (2004).
   PubMed Web of Science ®Google Scholar
• Eaddy M, Bramley T, Regan T. Time to antidepressant discontinuation: a comparison of controlled-release paroxetine and immediate-release selective serotonin-reuptake inhibitors. Manag. Care Interface16(12), 22–27 (2003).
   PubMedGoogle Scholar
• Rush AJ, Trivedi MH, Wisniewski SR et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N. Engl. J. Med.354(12), 1231–1242 (2006).
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Fava M, Wisniewski SR et al. Medication augmentation after the failure of SSRIs for depression. N. Engl. J. Med.354(12), 1243–1252 (2006).
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Staskin DR. Advances in drug delivery: improved bioavailability and drug effect. Curr. Urol. Rep.3(6), 439–444 (2002).
   PubMedGoogle Scholar
• Varley CK. Psychopharmacological treatment of major depressive disorder in children and adolescents. JAMA290(8), 1091–1093 (2003).
   PubMed Web of Science ®Google Scholar